Ruth M O'regan

List of Publications by Year
in descending order

50 papers	1,998 citations	430874 18 h-index	330143 37 g-index
51 all docs	51 docs citations	51 times ranked	3490 citing authors

#	Article	IF	Citations
1	Triple-negative breast cancer in African-American women: disparities versus biology. Nature Reviews Cancer, 2015, 15, 248-254.	28.4	342
2	Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 161, 279-287.	2.5	335
3	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment, 2009, 113, 357-370.	2.5	332
4	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 2016, 34, 2115-2124.	1.6	141
5	FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget, 2015, 6, 4757-4772.	1.8	101
6	AR Signaling in Breast Cancer. Cancers, 2017, 9, 21.	3.7	81
7	Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 139-147.	2.5	75
8	Role of the androgen receptor in triple-negative breast cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 186-93.	0.3	68
9	The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 982-993.	0.9	50
10	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Science Translational Medicine, 2021, 13, eabd4811.	12.4	48
11	In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemotherapy and Pharmacology, 2010, 65, 697-706.	2.3	46
12	Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. Clinical Cancer Research, 2006, 12, 2255-2263.	7.0	34
13	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer, 2021, 2, 658-671.	13.2	34
14	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. Journal of Clinical Oncology, 2013, 31, 505-505.	1.6	34
15	mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 859-872.	3.4	31
16	Hormone Receptor-Positive Breast Cancer HasÂaÂWorse Prognosis in Male Than in FemaleÂPatients. Clinical Breast Cancer, 2017, 17, 356-366.	2.4	29
17	Final Results of a Phase II Trial of Preoperative TAC (Docetaxel/Doxorubicin/Cyclophosphamide) in Stage III Breast Cancer. Clinical Breast Cancer, 2005, 6, 163-168.	2.4	23
18	Optimizing Endocrine Therapy for Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e56-e64.	4.9	21

#	Article	IF	Citations
19	Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling. Cancers, 2019, 11, 2039.	3.7	19
20	Therapy after cyclinâ€dependent kinase inhibition in metastatic hormone receptorâ€positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer, 2020, 126, 3400-3416.	4.1	19
21	High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer toÂaÂNovel Nonanthracycline Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2015, 15, 31-36.	2.4	15
22	Social media and clinical trials: The pros and cons gain context when the patient is at the center. Cancer, 2018, 124, 4618-4621.	4.1	15
23	African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Research and Treatment, 2017, 166, 743-755.	2.5	14
24	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. Clinical Breast Cancer, 2021, 21, 509-520.	2.4	13
25	Adjuvant Endocrine Therapy. Cancer Treatment and Research, 2018, 173, 15-29.	0.5	12
26	Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment, 2020, 183, 617-627.	2.5	12
27	Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+â€‰and FOXP3+â€‰immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast Cancer Research and Treatment, 2020, 183, 599-606.	2.5	11
28	A phase I study of talazoparib (<scp>BMN</scp> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<scp>NCI9782</scp>). Cancer Medicine, 2022, 11, 3969-3981.	2.8	11
29	The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 1112-1112.	1.6	8
30	Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer. Biomarkers, 2010, 15, 191-193.	1.9	7
31	Evaluation of Prognosis in Hormone Receptorâ€“Positive/HER2-Negative and Lymph Nodeâ€“Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clinical Breast Cancer, 2018, 18, 347-352.	2.4	5
32	Adjuvant cyclinâ€dependent kinase 4/6 inhibition in hormone receptorâ€“positive breast cancer: One Monarch to rule them all?. Cancer, 2021, 127, 3302-3309.	4.1	3
33	Improving Outcomes for High-Risk Hormone Receptorâ€“Positive Breast Cancer With CDK Inhibition. Journal of Clinical Oncology, 2022, 40, 1142-1146.	1.6	3
34	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, 188-196.	2.4	2
35	Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.. Journal of Clinical Oncology, 2013, 31, 1007-1007.	1.6	2
36	Race, breast cancer, and prognosis: Where biology is queen?. Cancer, 2019, 125, 3104-3106.	4.1	1

#	Article	IF	Citations
37	Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2â€“ locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology, 2013, 31, TPS650-TPS650.	1.6	1
38	Endocrine Therapy for Metastatic Disease: Reversing Resistance. Current Breast Cancer Reports, 2010, 2, 114-119.	1.0	0
39	Progress in breast cancer research amid the COVIDâ€19 gloom. Cancer, 2020, 126, 3809-3810.	4.1	0
40	Implementation of a chemotherapy stewardship process. American Journal of Health-System Pharmacy, 2020, 77, 1243-1248.	1.0	0
41	Adherence rates to endocrine therapy among African American women with stage I-III, hormone receptor-positive breast cancer treated at Grady Memorial Hospital in Atlanta, Georgia.. Journal of Clinical Oncology, 2013, 31, e11582-e11582.	1.6	0
42	Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 576-576.	1.6	0
43	Adjuvant anthracyclines: time for a change of heart?. Oncology, 2011, 25, 140, 142.	0.5	0
44	Neratinib: an option for HER2-positive metastatic breast cancer. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 15, 1-20.	0.3	0
45	Treatment goals in the management of HER2-positive metastatic breast cancer. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 15, 3-6.	0.3	0
46	Neratinib: an option for HER2-positive metastatic breast cancer--Q&A. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 15, 15-17.	0.3	0
47	Neratinib in the early-stage/extended adjuvant breast cancer patient. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 12, 1-20.	0.3	0
48	Neratinib in early-stage breast cancer: clinical trial data. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 12, 7-10.	0.3	0
49	Neratinib in the early-stage/extended adjuvant breast cancer patient: Q&A. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 12, 16-17.	0.3	0
50	Abstract P2-10-08: Assessment of risk factors for HER2+ breast cancer recurrence: A literature review. Cancer Research, 2022, 82, P2-10-08-P2-10-08.	0.9	0